GleamWall
中文EN

IMMX Immix Biopharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1873835 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-96.3%
TTM EPS YoY-7.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-26.9%
ROA-25.3%
ROIC (approx.)-1,121.6%
Asset turnover—

Leverage & solvency

Liabilities / assets3.1%
Debt / equity0.00x
Current ratio33.72x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-0.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$16.26M$11.29M
SG&A expense$13.70M$11.38M
Operating income-$29.96M-$22.67M
Pretax income-$29.40M-$21.66M
Income tax$37,724$41,037
Net income-$29.44M-$21.61M
EBITDA-$29.71M-$22.64M
EPS (basic)-0.89-0.76
EPS (diluted)-0.89-0.76
Weighted avg. shares (diluted)32.97M28.29M
Balance sheet
Cash & equivalents$93.93M$17.68M
Short-term investments$6.48M—
Current assets$101.24M$20.20M
PP&E, net$2.52M$1.74M
Total assets$104.84M$22.95M
Current liabilities$10.11M$8.69M
Total liabilities$11.04M$9.70M
Shareholders' equity$93.80M$13.25M
Shares outstanding52.95M27.54M
Cash flow statement
Operating cash flow-$23.93M-$14.60M
Capital expenditure$732,925$1.18M
Free cash flow-$24.66M-$15.77M
Investing cash flow-$7.21M-$1.18M
Financing cash flow$107.39M$15.95M
Depreciation & amortization$245,747$32,941
Stock-based compensation$2.44M$3.02M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.